Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JLP-1901 vs JC-001 in Healthy Subjects
NCT06171880Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JLP-1901 in hepatitis B (HBV) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve over 24H and Maximum Plasma Concentration at 24 hours. Started Feb 2022; status: completed.
02
Drugs
JLP-1901
03
Conditions
hepatitis B (HBV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06171880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171880.